{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:49:28Z","timestamp":1754261368759},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.pharmthera.2016.06.017","type":"journal-article","created":{"date-parts":[[2016,7,3]],"date-time":"2016-07-03T00:09:34Z","timestamp":1467504574000},"page":"78-82","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease"],"prefix":"10.1016","volume":"169","author":[{"given":"Sarah","family":"Dawson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.pharmthera.2016.06.017_bb0005","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.2337\/diacare.28.9.2176","article-title":"Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients","volume":"28","author":"Avignon","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.06.017_bb0010","first-page":"401","article-title":"Cytokine & growth factor reviews","volume":"24","author":"Baud'huin","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.06.017_bb0015","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.06.017_bb0020","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1161\/01.ATV.0000236428.91125.e6","article-title":"Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE\u2212\/\u2212 mice","volume":"26","author":"Bennett","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.06.017_bb0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10456-013-9337-x","article-title":"Mechanistic study of the proangiogenic effect of osteoprotegerin","volume":"16","author":"Benslimane-Ahmim","year":"2013","journal-title":"Angiogenesis"},{"issue":"S3","key":"10.1016\/j.pharmthera.2016.06.017_bb0030","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.06.017_bb0035","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.06.017_bb0040","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.06.017_bb0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.exger.2009.07.004","article-title":"Microarray analysis of senescent vascular smooth muscle cells: a link to atherosclerosis and vascular calcification","volume":"44","author":"Burton","year":"2009","journal-title":"Exp Gerontol"},{"issue":"11","key":"10.1016\/j.pharmthera.2016.06.017_bb0050","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/ATVBAHA.113.301755","article-title":"Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification","volume":"33","author":"Callegari","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.pharmthera.2016.06.017_bb0055","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circ Res"},{"issue":"23","key":"10.1016\/j.pharmthera.2016.06.017_bb0060","doi-asserted-by":"crossref","first-page":"20659","DOI":"10.1074\/jbc.M010153200","article-title":"Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis","volume":"276","author":"Collin-Osdoby","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.06.017_bb0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/2045-8932.94819","article-title":"Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension","volume":"2","author":"Condliffe","year":"2012","journal-title":"Pulm Circ"},{"issue":"8","key":"10.1016\/j.pharmthera.2016.06.017_bb0070","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/ijc.21606","article-title":"Osteoprotegerin (OPG)\u2014a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?","volume":"118","author":"Cross","year":"2006","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.pharmthera.2016.06.017_bb0075","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.pharmthera.2016.06.017_bb0080","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1084\/jem.20112716","article-title":"Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension","volume":"209","author":"Hameed","year":"2012","journal-title":"J Exp Med"},{"issue":"25 Suppl","key":"10.1016\/j.pharmthera.2016.06.017_bb0085","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.06.017_bb0090","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.06.017_bb0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/14017431.2012.685491","article-title":"Osteoprotegerin as a marker of atherosclerosis: a systematic update","volume":"46","author":"Hosbond","year":"2012","journal-title":"Scand Cardiovasc J"},{"issue":"24","key":"10.1016\/j.pharmthera.2016.06.017_bb0100","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1161\/CIRCULATIONAHA.114.006974","article-title":"Advances in therapeutic interventions for patients with pulmonary arterial hypertension","volume":"130","author":"Humbert","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.06.017_bb0105","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1183\/09031936.00078411","article-title":"ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a referral centre","volume":"39","author":"Hurdman","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.06.017_bb0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clinbiochem.2011.12.003","article-title":"Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions","volume":"45","author":"Karatolios","year":"2012","journal-title":"Clin Biochem"},{"issue":"12","key":"10.1016\/j.pharmthera.2016.06.017_bb0115","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.clinbiochem.2013.05.048","article-title":"Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis","volume":"46","author":"Kim","year":"2013","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.06.017_bb0120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mvr.2008.06.004","article-title":"Role of \u03b1v integrin in osteoprotegerin-induced endothelial cell migration and proliferation","volume":"76","author":"Kobayashi-Sakamoto","year":"2008","journal-title":"Microvasc Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.06.017_bb0125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1757-2215-6-82","article-title":"Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis","volume":"6","author":"Lane","year":"2013","journal-title":"J Ovarian Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.06.017_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1757-2215-5-34","article-title":"Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis","volume":"5","author":"Lane","year":"2012","journal-title":"J Ovarian Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.06.017_bb0135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2353\/ajpath.2008.070395","article-title":"Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension","volume":"172","author":"Lawrie","year":"2008","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.06.017_bb0140","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/jcb.21121","article-title":"Ovariectomy-induced bone loss occurs independently of B cells","volume":"100","author":"Li","year":"2007","journal-title":"J Cell Biochem"},{"issue":"8","key":"10.1016\/j.pharmthera.2016.06.017_bb0145","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1163\/156856208784909381","article-title":"Heparin-regulated delivery of osteoprotegerin promotes vascularization of implanted hydrogels","volume":"19","author":"McGonigle","year":"2008","journal-title":"J Biomater Sci Polym Ed"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.06.017_bb0150","first-page":"411","article-title":"Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(\u2212\/\u2212) mice","volume":"117","author":"Morony","year":"2008"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.06.017_bb0155","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/jc.2004-1895","article-title":"Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes","volume":"90","author":"Mosheimer","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.06.017_bb0160","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/art.20352","article-title":"Expression and function of RANK in human monocyte chemotaxis","volume":"50","author":"Mosheimer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2016.06.017_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2012.06.004","article-title":"No influences of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells","author":"Olesen","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.06.017_bb0170","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00125-004-1652-8","article-title":"Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha","volume":"48","author":"Olesen","year":"2005","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.06.017_bb0175","article-title":"Osteoprotegerin in cardiometabolic disorders","volume":"2015","author":"P\u00e9rez de Ciriza","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"6","key":"10.1016\/j.pharmthera.2016.06.017_bb0180","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1091\/mbc.E04-01-0059","article-title":"The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival","volume":"15","author":"Pritzker","year":"2004","journal-title":"Mol Biol Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.06.017_bb0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02049","article-title":"Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients","volume":"154","author":"Rasmussen","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.06.017_bb0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbrc.2011.02.117","article-title":"Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin","volume":"407","author":"Schoppet","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.06.017_bb0195","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1593\/neo.03421","article-title":"Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand","volume":"6","author":"Secchiero","year":"2004","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.06.017_bb0200","first-page":"309","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997"},{"issue":"10-11","key":"10.1016\/j.pharmthera.2016.06.017_bb0205","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.clinbiochem.2011.04.016","article-title":"Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals","volume":"44","author":"St\u0119pie\u0144","year":"2011","journal-title":"Clin Biochem"},{"issue":"4","key":"10.1016\/j.pharmthera.2016.06.017_bb0210","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbrc.2011.07.001","article-title":"Expression of RANKL\/OPG during bone remodeling in vivo","volume":"411","author":"Tanaka","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.06.017_bb0215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","article-title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis","volume":"234","author":"Tsuda","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"25 Suppl","key":"10.1016\/j.pharmthera.2016.06.017_bb0220","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","article-title":"Relevant issues in the pathology and pathobiology of pulmonary hypertension","volume":"62","author":"Tuder","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pharmthera.2016.06.017_bb0225","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jacc.2004.06.076","article-title":"Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction","volume":"44","author":"Ueland","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pharmthera.2016.06.017_bb0230","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.jacc.2005.08.039","article-title":"Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients","volume":"46","author":"Ueland","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.06.017_bb0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11897-012-0088-6","article-title":"TNF revisited: osteoprotegerin and TNF-related molecules in heart failure","volume":"9","author":"Ueland","year":"2012","journal-title":"Curr Heart Fail Rep"},{"issue":"43","key":"10.1016\/j.pharmthera.2016.06.017_bb0240","doi-asserted-by":"crossref","first-page":"31601","DOI":"10.1074\/jbc.M706078200","article-title":"Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways","volume":"282","author":"Vitovski","year":"2007","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmthera.2016.06.017_bb0245","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","article-title":"Osteoprotegerin deficiency and juvenile Paget's disease","volume":"347","author":"Whyte","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharmthera.2016.06.017_bb0250","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1074\/jbc.273.9.5117","article-title":"Characterization of structural domains of human osteoclastogenesis inhibitory factor","volume":"273","author":"Yamaguchi","year":"1998","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.pharmthera.2016.06.017_bb0255","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmthera.2016.06.017_bb0260","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2007-01-068395","article-title":"Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo","volume":"110","author":"Zauli","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2016.06.017_bb0265","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00018-008-8536-x","article-title":"Role of full-length osteoprotegerin in tumor cell biology","volume":"66","author":"Zauli","year":"2009","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.pharmthera.2016.06.017_bb0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.atherosclerosis.2005.01.042","article-title":"Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease","volume":"182","author":"Ziegler","year":"2005","journal-title":"Atherosclerosis"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T19:55:05Z","timestamp":1536609305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816301073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":54,"alternative-id":["S0163725816301073"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.06.017","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}